{"id":"NCT00180479","sponsor":"Abbott Medical Devices","briefTitle":"SPIRIT III Clinical Trial of the XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)","officialTitle":"SPIRIT III: A Clinical Evaluation of the Investigational Device XIENCE V® Everolimus Eluting Coronary Stent System (EECSS) in the Treatment of Subjects With de Novo Native Coronary Artery Lesions","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-06","primaryCompletion":"2006-12","completion":"2011-11","firstPosted":"2005-09-16","resultsPosted":"2008-12-15","lastUpdate":"2011-11-23"},"enrollment":1002,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"TREATMENT"},"conditions":["Stents","Coronary Artery Disease","Total Coronary Occlusion","Coronary Artery Restenosis","Stent Thrombosis","Vascular Disease","Myocardial Ischemia","Coronary Artery Stenosis"],"interventions":[{"type":"DEVICE","name":"XIENCE V® Everolimus Eluting Coronary Stent","otherNames":["XIENCE V® Everolimus Eluting Coronary Stent System"]},{"type":"DEVICE","name":"TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent","otherNames":["TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent System"]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"ACTIVE_COMPARATOR"}],"summary":"This study is divided into 5 arms:\n\n1. Randomized Clinical Trial (RCT): Prospective, randomized, active-controlled, single blind, parallel two-arm multi-center clinical trial in the United States (US) comparing XIENCE V® Everolimus Eluting Coronary Stent System (CSS) (2.5, 3.0, 3.5 mm diameter stents) to the Food and Drug Administration (FDA) approved commercially available active control TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent (TAXUS® EXPRESS2™ PECS) System\n2. US 2.25 mm non-randomized arm using 2.25 mm diameter XIENCE V® Everolimus Eluting CSS\n3. US 4.0 mm non-randomized arm using 4.0 mm diameter XIENCE V® Everolimus Eluting CSS\n4. US 38 mm non-randomized arm using 38 mm in length XIENCE V® Everolimus Eluting CSS\n5. Japanese non-randomized arm using XIENCE V® Everolimus Eluting CSS (2.5, 3.0, 3.5, 4.0 mm diameter stents) in Japan\n\nThe TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent System is Manufactured by Boston Scientific.","primaryOutcome":{"measure":"Primary Endpoint: In-segment Late Loss (LL)","timeFrame":"240 days","effectByArm":[{"arm":"XIENCE V® EECSS","deltaMin":0.14,"sd":0.41},{"arm":"TAXUS® EXPRESS2™ ECSS","deltaMin":0.28,"sd":0.48}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":7},"locations":{"siteCount":65,"countries":["United States"]},"refs":{"pmids":["18430909","19171853","19530147","25940520","24746650","22115661","22017936","21232716","21232715"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":219},"commonTop":["Angina pectoris","Catheter site haematoma","Myocardial infarction"]}}